News
We send the latest information from SMC Laboratories.
FDA-National Center for Toxicological Research’s publication in Frontiers in Genetics.
SMC announced that FDA-National Center for Toxicological Research (NCTR) published the results of a study using STAM™ model in Frontiers in Genetics. Title: Gene Expression and DNA Methylation Alterations During Non-alcoholic Steatohepatitis-Associated Liver Carcinogenesis Read more…https://www.ncbi.nlm.nih.gov/pubmed/31191608
Enanta Pharmaceuticals, Inc’s publication on the International Journal of Gastroenterology.
SMC announces that Enanta Pharmaceuticals, Inc. has published the results of a study using the STAM™ model in the International Journal of Gastroenterology. Title: Characterization of EDP-305, a Highly Potent and Selective Farnesoid X Receptor Agonist, for the Treatment of Non-alcoholic Steatohepatitis Read more…. http://www.sciencepublishinggroup.com/journal/paperinfo?journalid=282&doi=10.11648/j.ijg.20190301.12
Kanagawa University of Human Services’ publication on Experimental Animals.
SMC announced that Kanagawa University of Human Services has published the results of a study using STAM™ model on Experimental Animals. Title: “Analysis of amino acid profiles of blood over time and biomarkers associated with non-alcoholic steatohepatitis in STAM™ mice” Read more…. https://www.ncbi.nlm.nih.gov/pubmed/31155606
Osaka Medical College’s presentation at DDW® 2019 in San Diego, CA.
SMC announced that Osaka Medical College presented results of a study using STAM™ model at poster presentation at DDW® 2019 in San Diego, CA, May 18-21, 2019. Title: “Influence of the O-GlcNAc Modification in Hepatic Carcinogenesis by Non-alcoholic Fatty Liver Disease”
TSUMURA & Co.’s presentation at DDW® 2019 in San Diego, CA.
SMC announced that TSUMURA & Co. presented results of a study using STAM™ model at poster presentation at DDW® 2019 in San Diego, CA, May 18-21, 2019. Title: “Change of Gut Microbiome after Treatment with the Traditional Japanese Medicine Daisaikoto is Associated with Improved Liver Steatosis in a Non-alcoholic Fatty Liver Mouse Model”
Pharmaxis Ltd’s publication on Journal of Cellular and Molecular Medicine.
SMC announced that Pharmaxis Ltd has published the results of a study using STAM™ model on Journal of Cellular and Molecular Medicine. Title: “The lysyl oxidase like 2/3 enzymatic inhibitor, PXS-5153A, reduces crosslinks and ameliorates fibrosis” Read more….https://www.ncbi.nlm.nih.gov/pubmed/30536539
Publication on Scientific Reports.
SMC announced that the results of a study in the STAM™ mouse model of NASH performed by SMC Laboratories Inc. has been published in Scientific Reports: Title: “Connectivity mapping of angiotensin-PPAR interactions involved in the amelioration of non-alcoholic steatohepatitis by Telmisartan” Read more…. https://www.ncbi.nlm.nih.gov/pubmed/30850637
Genentech, Inc’s publication on NPJ Precision Oncology.
SMC announced that Genentech, Inc. has published the results of a study using STAM™ model on NPJ Precision Oncology. Title: “Transcriptomic analysis of hepatocellular carcinoma reveals molecular features of disease progression and tumor immune biology” Read more….https://www.ncbi.nlm.nih.gov/pubmed/30456308